Journal of Neurology Neurosurgery and Psychiatry

Article	Citations
091 The East London Parkinson’s disease project – engaging a diverse population in research	149
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data	115
102 Levodopa and melanoma what do clinicians think?	104
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?	98
117 Who is the culprit – the virus or the anti-virus?	89
226  Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C]UCB-J PET	85
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease	80
35 Processing speed (PS) improvement in alcohol related brain damage (ARBD)	79
Navigating the presymptomatic frontier in genetic ALS and FTD	79
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes	78
094  Measuring neutralising antibodies (NAbs) to interferon-beta (IFNB) for multiple sclerosis (MS): a neglected practice?	76
005  Infusion associated reactions in ocrelizumab-treated multiple sclerosis patients	75
099  Safety and effectiveness of dimethyl fumarate in multiple sclerosis patients treated over 5 years	75
122  Neurological manifestations of haemophagocytic lymphohistiocytosis	68
102  The cost of misdiagnosis in POEMS syndrome	66
White matter hyperintensities and brain microbleeds in ataxia-telangiectasia: the Cambridge cohort	63
001  Machine learning accurately determines the population prevalence of Alzheimer’s disease based on microbiome profile	60
010  Safety and efficacy of long-term dimethyl fumarate treatment	57
201  Management of an unusual presentation of spontaneous intracranial hypotension (SIH)	56
184  Right data, right care	56
L-arginine and mitochondrial encephalomyopathy, lactic acidosis and stroke- like episodes (MELAS): a systematic review	55
238  Cogniton and mood disorder in cervical dystonia	55
164  Progressive multifocal leukoencephalopathy (PML) following autologous periph- eral blood stem cell transplantation for multiple myeloma	55
12 A pilot investigation of interoceptive accuracy, awareness, and sensibility in functional neurological disorder	52
West is best – a strongman with numb feet	52

091  CIDP mimic in a patient with HIV; An unusual presentation of POEMS syndrome	51
003  Neuroanatomical signatures of genetic risk for Alzheimer’s disease in healthy adults	50
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts	50
Early treatment of type II SMA slows rate of progression of scoliosis	49
114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease	49
Characterising ALS disease progression according to El Escorial and Gold Coast criteria	48
Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning	47
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy	46
101 Motor and non-motor features of prodromal PD	46
Neural (re)organisation of language and memory: implications for neuroplasticity and cognition	46
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis	45
Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study	45
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis	44
High frequency ofHTRA1ANDABCC6mutations in Japanese patients with adult-onset cerebral small vessel disease	44
143  Catastrophising cognitions in patients with psychogenic non-epileptic seizures compared to patients with epilepsy	44
Improved naming in patients with Broca’s aphasia with tDCS	40
006  Seizure focus prediction from seizure semiology: data-driven cortical probabilis- tic heatmaps from 4643 patients	39
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort	39
259  A novel mutation of protein kinase C gamma associated with spinocerebellar ataxia type 14	38
096  Maintenance IVIg safe prescribing – audit of proforma and traffic light risk assessment system in NHNN	38
039  Cerebral venous sinus thrombosis and COVID-19: causation or coincidence?	38
Late-onset epilepsy predicts future stroke: a systematic review and meta-analysis	38
235  Assessing coding of diagnosis for atypical parkinsonian syndromes	38
161  Two-centre audit of cannabidiol use in adults with Dravet syndrome	37
016  Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension	37
084  Is there a positive correlation between single breath count and forced vital capacity?	37
Effects of VNS stimulation on electrocorticography in patients with dual neuro- stimulation devices	36
Good outcomes after aggressive treatment of immune checkpoint inhibitor related myasthenia gravis: a case series	36
239  New de novo mutation in CACNA1a gene leading to episodic ataxia type 2	34
40 Temporal discounting and male depression	34
052 SKYLINE study design efficacy and safety of gantenerumab in participants at-risk for Alzheimer’s disease	33
The Scottish Epilepsy Deaths Study Score (SEDS Score): a risk prediction model for epilepsy-related deaths	33
066 The Utility of 18-FDG PET imaging in the preoperative workup for epilepsy surgery	31
178 Motor neurone disease and sociodemographic factors: a review	31
005 A case of xanthomatous hypophysitis presenting as recurrent pituitary adenoma	31
055 Assessment of MACE cognitive screener using efficiency indexes	30
106 Critical ischaemia without infarction presenting as progressive hemichorea: a case study and literature review	30
009 Asymmetric peri-optic cerebrospinal fluid space distension in cluster headache	30
110  UK multiple sclerosis service audit of 70 centres: MS-MDTs	30
Evaluation of MDS-PSP diagnostic criteria in a combined behavioural neurology and atypical parkinsonism service	30
132 Adverse prognostic factors predicting disease modifying therapies in MS: a real- world cohort	30
Real-world experience of gene therapy with onasemnogene-abeparvovec (Zolgensma®) for patients with SMA-type1 in UK	29
Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis	29
Dissociative seizures in the emergency room: room for improvement	29
Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea	28
Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile	28
Association of obesity with mild traumatic brain injury symptoms, inflammatory profile, quality of life and functional outcomes: a TRACK-TBI Study	28
CIDP trials and tribulations	28
Can brain signals and anatomy refine contact choice for deep brain stimulation in Parkinson’s disease?	28
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology	28

Temporal lobe epilepsy lateralisation and surgical outcome prediction using diffusion imaging	27
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry	27
Neuromodulation for the treatment of functional neurological disorder and somatic symptom disorder: a systematic review	27
Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride	27
Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards	27
Comparative neural correlates of DBS and MRgFUS lesioning for tremor control in essential tremor	27
021 Experience from a SARS-CoV2 neurology clinic at the national hospital of neurology and neurosurgery	27
049 Hippocampal place cell dysfunction in an APP knock-in mouse model of Alzheimer’s disease	26
028 Croydon neurology diagnostic coding of outpatients – the first year of experience	26
114 Pain and objectively measured cognitive performance in adults with multiple sclerosis: a systematic review	26
What, when and how should the information about neurodegenerative disease risk in iRBD be communicated?	26
219  MRI monitoring in MS patients prescribed disease monitoring treatments in Kings College Hospital	25
171 Urinary P75: a novel biomarker for motor neuron disease?	25
099 Thrombotic and haemorrhagic complications associated with PLEX, reducing the risks	25
222  DECISIve – DiagnosE using the Central veIn SIgn. A study comparing T2* MRI and lumbar puncture	25
010 Trigeminal neuralgia in diffuse scleroderma – a rare but recognised association	25
142 Discordance between neurologists and people with MS on the presence and burden of cognitive impairment	25
156 Association of locus of control with clinical and psychosocial aspects of living with multiple sclerosis	25
258  A case of two brothers: should we look beyond a diagnosis of cerebral palsy?	24
017  Year 1 performance of adveva® programme for patients taking cladribine tablets for relapsing-remitting multiple sclerosis	24
024  CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets	24
244  Idiopathic anosmia with motor impairment – a unique prodrome of Parkinson’s?	24
022  Functional genomics and transcriptomics further characterise and potentially improve diagnostic yield of hereditary ataxias	24
Biomarkers for brain injury and copper toxicity in Wilson’s disease: a diffusion tensor imaging study	24
199  Improving training in systems leadership management: a ‘Mini-Darzi’ approach	24
009  Abnormal blood-brain barrier permeability in progressive multiple sclerosis	24
026  Gene-environment interactions in multiple sclerosis: a UK Biobank study	24
046  Familial multiple sclerosis: a community-based epidemiology study in Cumbria	24
103  Virtual multiple sclerosis (MS) clinics during a global pandemic: the patients’ perspective	23
170  Did the atraumatic lumbar puncture needle campaign have any effect?	23
Serum level changes of the synaptic marker beta-synuclein in Alzheimer’s disease continuum and other dementias	23
Searches for biomarkers using highly sensitive techniques might reveal more about pathogenesis of a disease than provide clinically useful molecular tests	22
Validation of the hotspot for dorsolateral subthalamic nucleus targeting in deep brain stimulation surgery for Parkinson’s disease: a post hoc analysis of a randomised controlled trial	22
Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility	22
How effective is effective enough?	22
185 JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with SMA receiving risdiplam	22
Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis	22
047 Clinicopathological characteristics impacting on survival in sporadic CJD: insights from an international autopsy-confirmed series	22
Muscle biochemical and pathological diagnosis in Pompe disease	21
08 The economic cost of functional neurological disorders: a systematic review introduction	21
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies	21
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction	21
Quantification of muscle glycogen distribution in Pompe disease using 7 Tesla 13C NMR spectroscopy	21
APOE ɛ4dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction	21
MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis	21
Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course	21
Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention	21
Evoked mid-frontal activity predicts cognitive dysfunction in Parkinson’s disease	21
124  Symptoms of post-traumatic stress disorder are common after being diagnosed with multiple sclerosis	20
135  A national audit of service provision for patients with atypical parkinsonian syndrome	20
Unhealthy traits and risk of Parkinson’s disease: a mendelian randomisation study	20
Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study	20
187  Variation in training: Results from a survey of UK neurology trainees	20
078  The future of outpatient appointments: do patients with epilepsy prefer remote consultations?	20
Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion	20
091  Evaluation of remote assessments for multiple sclerosis in a real-world setting	20
14 Saving Adam from the apple: using transcranial magnetic stimulation as a transdiagnostically relevant tool to decrease cue-reactivity	19
054 Baseline characteristics of the Phase III GRADUATE studies: investigating subcu- taneous gantenerumab in early AD	19
064 Epilepsy and sociodemographic factors a review	19
128 Visuoperceptual deficits as measures of cognitive dysfunction in multiple sclerosis: a pilot study	19
080 IIH Life A prospective longitudinal cohort study of idiopathic intracranial hypertension	19
Attenuated heart-brain integration predicts functional non-epileptic seizures	19
25 ‘In a mist?’ – What is ‘brain fog’?	19
126 The provision of anti-CD20 therapy in inflammatory demyelinating disorders of the CNS during SARS-CoV-2	19
058 Does prolonging duration of monitoring in epilepsy monitoring unit improve diagnostic yield?	19
A novel neurodegenerative disease with multi-system features	19
039  Disease modifying treatments and cancer monitoring in MS; the need for a nation-wide disease registry	18
104  A case of natalizumab-related progressive multifocal leukoencephalopathy treated with pembrolizumab	18
124  MEGAbIT – the role of OPM MEG in assessment and diagnosis In mTBI	18
032  Improving access to inpatient ambulatory cardiac monitoring for acute stroke patients during the Covid-19 pandemic	18
225  A rare case of recurrent unsteadiness due to Miller Fisher syndrome	17
117  Sustained and rapid B-cell depletion with ofatumumab: population pharma- cokinetic B-cell modeling in relapsing MS patients	17
11 The experience of hearing life altering medical news? Perspectives from health professionals	17
Effects of immunotherapies and clinical outcomes in neurosarcoidosis : a retro- spective cohort study	17
044  Analysis of urgent acute medicine and ward referrals to neurology at the district hospital	17
Prescription opioid use in multiple sclerosis	17
030  Hepatitis C reactivation with fingolimod treatment for relapsing-remitting multiple sclerosis (RRMS)	17
043  Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis	17
Investigating colour vision and its structural correlates 15 years following a first demyelinating event	17
125  Towards an optimal multiple sclerosis patient case-load for a full-time MSologist	17

130  Does visual imagery vividness have a genetic basis? A genome-wide associa- tion study of 1019 individuals	16
Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study	16
IVIg-exposure and thromboembolic event risk: findings from the UK Biobank	16
Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex	16
Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study	16
Gene–environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures	16
Functional tremor developing after successful MRI-guided focused ultrasound thalamotomy for essential tremor	16
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations	16
Association between heavy alcohol consumption and cryptogenic ischaemic stroke in young adults: a case–control study	16
Visuospatial dysfunction predicts dementia-first phenoconversion in isolated REM sleep behaviour disorder	16
Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease	15
Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark	15
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial	15
Stratifying quality of life outcome in subthalamic stimulation for Parkinson’s disease	15
A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson’s disease	15
24 Intelligent sensing in ADHD trial (ISAT) – pilot study	15
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study	15
Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials	15
Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis	15
Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change	15
Can CANVAS due toRFC1biallelic expansions present with pure ataxia?	15
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort	15
Risk of secondary progressive multiple sclerosis after early worsening of disability	15
Time to treat the climate and nature crisis as one indivisible global health emergency	14
032 Supine hypertension and cardiovascular autonomic failure in patients with alpha-synucleinopathies	14
056 Online assessment and monitoring of cognitive decline in neurological conditions	14
153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS)	14
242  A systematic review on the benefit of multidisciplinary care for patients with atypical parkinsonian syndromes	14
086  Thymectomy in myasthenia gravis – a review of 36 patients	14
011  Progressive myoclonic epilepsy due to rare mitochondrial ND6 mutation, m.14487T>C	14
Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS	14
044 At what resolution does the brain perform computations?	14
Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon	14
Genomic features specific to the human lineage are associated with neurological diseases and intelligence	14
030  Emerging parkinsonism in the PREDICT-PD cohort after 5-year follow-up	14
247  Unusual presentation to an emergency department	14
195  Delayed transfer of care (DToC) in neuroscience across South London: an insight through patient journeys	14
Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses	14
Epigenetic clocks in neurodegenerative diseases: a systematic review	14
003  Systemic inflammation, erythrocyte fragility and multiple sclerosis	14
074  Long-term effect of idebenone in reducing respiratory function decline in patients with Duchenne muscular dystrophy	14
135  CMT with renal impairment: consider a dip	14
212  Preventing blindness for patients with optic disc swelling: improving care using transformative new technology	14
035  Diagnosis of secondary progressive multiple sclerosis in UK centres: results from the SPECTRUM project	14
204  Idiopathic intracranial hypertension in Wales: population characterisation, epidemiological trends and healthcare utilisation	13
Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease	13
070  What is seronegative neuromyelitis optica spectrum disorder?	13
006 A novel approach in the management of functional neurological disorder in the hyper-acute setting	13
Validation of MATCH score: a predictive tool for identification of patients with kelch-like protein-11 autoantibodies	13
Telomere length, in vivo Alzheimer’s disease pathologies and cognitive decline in older adults	13
Statin use and long-term risk of recurrent intracerebral haemorrhage: the MUCH-Italy	13
Do lower limb motor-evoked potentials predict walking outcomes post-stroke?	13
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy	13
8 Integrating dimensions of interoception in neuropsychiatry	13
Structural and functional alterations in the gustatory network underlie taste disturbances after lesional tremor therapy with MRgFUS	13
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience	13
Elevated serum β-synuclein predicts cognitive decline and progression to dementia	13
Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies	13
04 Should neuropsychiatry flow both ways? Neurology inreach into psychiatric hospital	13
30 Dissociation and its biological and clinical correlates in functional neurological disorder: a systematic review and meta-analysis	13
37 The medicolegal challenges in neuropsychiatry: an evaluation of mental capacity and legal frameworks	13
Changes in the heartbeat-evoked potential are associated with functional seizures	12
We hold these truths to be self-evident	12
Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada’s population	12
Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysis	12
Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study	12
Endovascular treatment for large-core ischaemic stroke: a meta-analysis of randomised controlled clinical trials	12
Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank	12
023 Impact of pandemic on neurologists and neurology practice	12
163  Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures	12
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, ph	12
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study	12
Characterising alexithymia in individuals with functional motor disorders: a cross-sectional analysis of the Italian Registry of Functional Motor Disorders	12
211  The prevalence and characteristics of multiple sclerosis-associated uveitis in UK biobank	11
138  Frey’s syndrome: a review of the aetiology and possible role of neurotrophic factors	11
205  Is it a brain tumour? Assessment on performance of the CNS two week wait pathway	11
100 Antiphospholipid-related chorea	11
164 The role of MEG in assessment and diagnosis in mTBI	11
048  Postprandial somnolence in people with multiple sclerosis	11
152  Automating the assessment of first seizure care pathways and clinical outcomes using electronic patient records	11
100  Making decisions and sharing information, the patient experience: the UK Multiple Sclerosis Register (UKMSR)	11
073 Fenfluramine exhibits disease-modifying effects in a mouse model of Dravet syndrome	11
42 Inhibition of personal memory retrieval in dissociative amnesia: a study of two cases	11
179  Improving respiratory screening and NIV assessment in motor neuron disease	11
267  When investigating stroke is a waste of time	11
185  An assessment of perceived gender disparity in platform and poster presenters at ABN conferences	11
Parallel Session 2: Neurodegeneration| Wed 18 May, 1115 – 1230|4 Novel complex motor behaviours in LGI1-autoantibody encephalitis	11
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study	10
Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients	10
Linking LRP12 CGG repeat expansion to inherited peripheral neuropathy	10
Multiple metal exposures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study	10
Safety of breast feeding during rituximab treatment in multiple sclerosis	10
The T1-weighted/T2-weighted ratio as a biomarker of anti-NMDA receptor encephalitis	10
21 How can we collaborate with experts-by-example to improve the ecological validity of computational psychiatry? A pilot study where the experts-by-experience are people with functional neurological	10
098  Treatment escalation in secondary progressive MS identified clinically and algorithmically in relapsing remitting (RR)MS	10